<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869115</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 0614-106</org_study_id>
    <secondary_id>PAREXEL Study Number : 98378</secondary_id>
    <nct_id>NCT00869115</nct_id>
  </id_info>
  <brief_title>Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Escalating Dose Phase I Interaction Study to Evaluate the Pharmacokinetics, Tolerability and Pharmacodynamics of Three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion in Combination With Chronic Oral Digoxin Treatment in Patients With Controlled Cardiac Failure and Decreased Left Ventricular Systolic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study explores a potential drug-drug interaction between istaroxime and digoxin in&#xD;
      patients with stable CHF on chronic oral digoxin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double blind, placebo controlled, escalating dose phase&#xD;
      I interaction study. The three dose levels of istaroxime or placebo will be randomized&#xD;
      sequentially to three cohorts (I to III) of 16 patients each (12 patients on istaroxime and 4&#xD;
      patients on placebo). Digoxin will be administered non blinded in all patients, once daily in&#xD;
      the morning after a standardized breakfast, continuing with previously personalized dosage&#xD;
      schedule during the screening period, treatment period, post treatment period and follow up&#xD;
      period. Prior to accrual of cohorts II and III, a Data Monitoring Committee (DMC) will advise&#xD;
      on the continuation to the next istaroxime dose, based on a predetermined safety review.&#xD;
&#xD;
      This 37 day study includes a screening period (Days -21 to -1), a treatment period (Day 1), a&#xD;
      post treatment period (Days 2-4), and a follow up period (which includes one patient visit on&#xD;
      Day 14). Patients will be confined in the phase I research center from Day -2 to Day 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was not started due to a re-evaluation of the istaroxime development program&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints : Istaroxime PK parameters: - Istaroxime and Istaroxime metabolites (PST2915/2922/3093) plasma concentrations - Istaroxime and Istaroxime metabolites (PST2915/2922/3093) urine concentrations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic endpoints : Digoxin PK parameters: - Digoxin plasma concentrations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints: - Incidence of adverse events; - Change in vital signs; - Change in 12-lead ECG parameters; - Incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous EC</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic endpoints: - Change in echocardiographic parameters; - Change in SBP; - Change in non invasive cardiac output (Impedance cardiography) parameters.</measure>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREATMENT 0.5 μg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREATMENT 1.0 μg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TREATMENT 1.5 μg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istaroxime</intervention_name>
    <description>Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istaroxime</intervention_name>
    <description>Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istaroxime</intervention_name>
    <description>Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Istaroxime</intervention_name>
    <description>Placebo continuous i.v. infusion for 24 hours</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main screening inclusion criteria :&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Male or female patients ≥18 years;&#xD;
&#xD;
          -  Female patients of childbearing potential must not be pregnant;&#xD;
&#xD;
          -  Chronic stable cardiac function impairment (no change in heart failure medication over&#xD;
             the last 3 months and without any dosage adjustment in the last 4 weeks);&#xD;
&#xD;
          -  Systolic blood pressure (SBP) of ≥ 90 mmHg and ≤ 140 mmHg;&#xD;
&#xD;
          -  LVEF ≤ 35% by any method (to be performed at screening if not measured within the last&#xD;
             12 months);&#xD;
&#xD;
          -  Chronic treatment (i.e. once daily dosing without interruption) with oral digoxin&#xD;
             started at least 3 months prior to study entry and without any concomitant&#xD;
             administration of other positive inotropic drugs;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Main screening exclusion criteria :&#xD;
&#xD;
          -  Need for current or intermittent intravenous positive inotrope administration within&#xD;
             the preceding 6 months, or hemodynamic support devices;&#xD;
&#xD;
          -  Acute coronary syndrome within the past 3 months;&#xD;
&#xD;
          -  Coronary artery bypass graft or percutaneous coronary intervention within the past 3&#xD;
             months;&#xD;
&#xD;
          -  Stroke within the past 6 months;&#xD;
&#xD;
          -  Atrial fibrillation or uncontrolled heart rate (HR) (&gt; 100 beats per minute [bpm]);&#xD;
&#xD;
          -  Significant arrhythmia or second or third degree atrio-ventricular block;&#xD;
&#xD;
          -  Valvular disease as the primary cause of HF;&#xD;
&#xD;
          -  Significant ECG abnormalities as assessed by appropriately qualified physician or&#xD;
             investigator including QTcF &gt;450;&#xD;
&#xD;
          -  Positive testing for Human Immunodeficiency Virus (HIV), Hepatitis B and/or Hepatitis&#xD;
             C;&#xD;
&#xD;
        Main randomization exclusion criteria:&#xD;
&#xD;
          -  HR &gt; 100 bpm or &lt; 50 bpm;&#xD;
&#xD;
          -  Serum potassium &gt; 5.3 mmol/L or &lt; 3.8 mmol/L and magnesium &gt; 1.1 mmol/L or &lt; 0.6&#xD;
             mmol/L,&#xD;
&#xD;
          -  TN I &gt; ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <link>
    <url>http://www.debiopharm.com</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Valentini G, Sabbah HN; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008 Jun 10;51(23):2276-85. doi: 10.1016/j.jacc.2008.03.015. Epub 2008 Apr 9.</citation>
    <PMID>18534276</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <name_title>Hein Van Ingen, Medical Director</name_title>
    <organization>Debiopharm S.A.</organization>
  </responsible_party>
  <keyword>Digoxin</keyword>
  <keyword>Inotropes</keyword>
  <keyword>Lusitropic agents</keyword>
  <keyword>Istaroxime</keyword>
  <keyword>Debio 0614</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

